Associations - HER-2 mutation

HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	afatinib Resistant: A2 - Guideline afatinib Resistant : A2	afatinib Resistant: A2 - Guideline afatinib Resistant : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	trastuzumab Resistant: A2 - Guideline trastuzumab Resistant : A2	trastuzumab Resistant: A2 - Guideline trastuzumab Resistant : A2
HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2	ado-trastuzumab emtansine Sensitive: A2 - Guideline ado-trastuzumab emtansine Sensitive : A2
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
HER-2 mutation	Colorectal Cancer	HER-2 mutation	Colorectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2	tarloxotinib bromide Sensitive: C2 – Inclusion Criteria tarloxotinib bromide Sensitive : C2
HER-2 mutation	Hormone Receptor Positive Breast Cancer	HER-2 mutation	Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria trastuzumab + neratinib Sensitive : C2
HER-2 mutation	Gastric Cancer	HER-2 mutation	Gastric Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2

Unlock More with VERI